CN109475558A - 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 - Google Patents

通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 Download PDF

Info

Publication number
CN109475558A
CN109475558A CN201780046536.9A CN201780046536A CN109475558A CN 109475558 A CN109475558 A CN 109475558A CN 201780046536 A CN201780046536 A CN 201780046536A CN 109475558 A CN109475558 A CN 109475558A
Authority
CN
China
Prior art keywords
drug
cancer
compound
cell
folate receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780046536.9A
Other languages
English (en)
Chinese (zh)
Inventor
P.S.罗
B.王
C.P.利蒙
Y.J.卢
L.W.惠勒二世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Research Foundation
Endocyte Inc
Original Assignee
Purdue Research Foundation
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation, Endocyte Inc filed Critical Purdue Research Foundation
Priority to CN202210697024.1A priority Critical patent/CN114903890A/zh
Publication of CN109475558A publication Critical patent/CN109475558A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
CN201780046536.9A 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法 Pending CN109475558A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210697024.1A CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662341587P 2016-05-25 2016-05-25
US62/341587 2016-05-25
PCT/US2017/034537 WO2017205661A1 (en) 2016-05-25 2017-05-25 Method of treating cancer by targeting myeloid-derived suppressor cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210697024.1A Division CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN109475558A true CN109475558A (zh) 2019-03-15

Family

ID=60412652

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780046536.9A Pending CN109475558A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
CN202210697024.1A Pending CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210697024.1A Pending CN114903890A (zh) 2016-05-25 2017-05-25 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法

Country Status (8)

Country Link
US (2) US20190216935A1 (enExample)
EP (1) EP3463367A4 (enExample)
JP (1) JP7278777B2 (enExample)
KR (1) KR102489277B1 (enExample)
CN (2) CN109475558A (enExample)
AU (1) AU2017271550B2 (enExample)
IL (1) IL263059B2 (enExample)
WO (1) WO2017205661A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108710A1 (en) * 2018-08-07 2020-02-13 Purdue Research Foundation Rejuvenation of car t cell
AU2020310141A1 (en) 2019-07-08 2022-02-03 Purdue Research Foundation Compounds and methods for the treatment and prevention of fibrotic disease states and cancer
AU2021305193A1 (en) * 2020-07-08 2023-02-09 Purdue Research Foundation Compounds, compositions, and methods for the treatment of fibrotic diseases and cancer
KR20240140961A (ko) * 2022-03-08 2024-09-24 주식회사 코넥스트 콜라게네이즈, 칼슘, 히스티딘 및 글리신를 포함하는 조성물 및 콜라게네이즈의 안정화 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
CN104869998A (zh) * 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279304A1 (en) * 2005-08-19 2007-02-22 Endocyte, Inc. Multi-drug ligand conjugates
CA2793657A1 (en) * 2010-03-18 2011-09-22 Colorado State University Research Foundation Myeloid derived suppressor cell inhibiting agents
EP2701722A4 (en) * 2011-04-28 2014-12-31 Univ Southern California Human myeloid derived suppressor cell cancer markers
US9550992B2 (en) * 2011-12-02 2017-01-24 University Of South Florida Compositions and methods for modulating myeloid derived suppressor cells
WO2013169913A1 (en) * 2012-05-08 2013-11-14 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Predictors of patient response to interferon-a therapy
CN112587671A (zh) * 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
WO2014201245A1 (en) * 2013-06-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
SG11201607705XA (en) * 2014-03-19 2016-10-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20170266303A1 (en) * 2014-11-25 2017-09-21 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
WO2016148674A1 (en) * 2015-03-13 2016-09-22 Endocyte, Inc. Conjugates for treating diseases

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102549434A (zh) * 2009-07-31 2012-07-04 恩多塞特公司 叶酸盐靶向的诊断和治疗
CN104869998A (zh) * 2012-10-16 2015-08-26 恩多塞特公司 含有非天然氨基酸的药物递送缀合物以及其使用方法
WO2016027273A1 (en) * 2014-08-19 2016-02-25 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Methods for predicting and monitoring cancer patients' response to treatment by measuring myeloid derived suppressor cells (mdscs)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
（美）莱登著: "《肿瘤转移 生物学基础与治疗》", 31 May 2015, 复旦大学出版社 *
FRANCESCO DE SANCTIS等: "MDSCs in cancer: conceiving new prognostic and therapeutic targets", 《BIOCHIMICA ET BIOPHYSICA ACTA》 *
GERRIT JANSEN等: "Novel insights in folate receptors and transporters: implications for disease and treatment of immune diseases and cancer", 《PTERIDINES》 *
GREGORY M CRESSWELL等: "Folate Receptor Beta Designates Immunosuppressive Tumor-Associated Myeloid Cells that Can Be Reprogrammed with Folate-Targeted Drugs", 《CANCER RES》 *
朱广迎主编: "《放射肿瘤学 3版》", 31 August 2015, 科学技术文献出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116283709A (zh) * 2023-01-13 2023-06-23 华中科技大学同济医学院附属同济医院 一种脂滴包被蛋白3的抑制剂及其应用

Also Published As

Publication number Publication date
KR20190021261A (ko) 2019-03-05
IL263059B1 (en) 2024-10-01
JP2019519524A (ja) 2019-07-11
IL263059A (en) 2018-12-31
AU2017271550A1 (en) 2018-12-06
RU2018145750A (ru) 2020-06-25
EP3463367A1 (en) 2019-04-10
RU2018145750A3 (enExample) 2020-07-30
NZ748427A (en) 2025-05-30
CN114903890A (zh) 2022-08-16
US20210170035A1 (en) 2021-06-10
AU2017271550B2 (en) 2023-11-02
WO2017205661A1 (en) 2017-11-30
KR102489277B1 (ko) 2023-01-16
IL263059B2 (en) 2025-02-01
EP3463367A4 (en) 2020-01-29
US20190216935A1 (en) 2019-07-18
JP7278777B2 (ja) 2023-05-22
BR112018074119A2 (pt) 2019-03-06
CA3025309A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
ES2946507T3 (es) Imidazolonilquinolinas y su uso como inhibidores de ATM cinasa
JP6798890B2 (ja) グルタミナーゼ阻害剤との併用療法
CN106074368B (zh) Pfkfb3抑制剂和用作抗癌治疗剂的方法
CN109475558A (zh) 通过靶向骨髓衍生的抑制细胞而治疗癌症的方法
JP6588546B2 (ja) 新規抗癌剤としての置換２，４ジアミノキノリン
BR112021002250A2 (pt) compostos de ligação ao receptor de il-2
CN113956238A (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
JP2025063195A (ja) トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用
CN110312517A (zh) 促黄体激素释放激素受体(lhrh-r)缀合物及其用途
TW201801751A (zh) 靶向構建體及其製劑
JP2024531258A (ja) 微小管阻害剤に基づく抗体薬物複合体
TW202222311A (zh) 結合熱休克蛋白９０（ｈｓｐ９０）之共軛體和彼之調製劑
TW202340226A (zh) 碳酸酐酶ix配位體
JP2020515582A (ja) 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート
JP2018518509A (ja) 白金化合物、組成物及びその使用
EP4436578A1 (en) Combination therapy comprising an fgfr inhibitor and a kras inhibitor
CN106232115A (zh) 用于治疗抗性的癌症的预防或治疗性组合物
CN104861063A (zh) 靶向her2阳性肿瘤的化合物和组合物
WO2023222019A1 (zh) 配体药物偶联物及其应用
CN115884980A (zh) 肽铂络合物及其使用方法
KR20160133005A (ko) 암 치료법의 조합
CN116693505B (zh) 一种靶向降解egfr蛋白的化合物及其制法和应用
CN110678204A (zh) 用于靶向肿瘤相关巨噬细胞的叶酸缀合物
CN121419788A (zh) 用于体内递送有效载荷的基于四嗪的靶向剂
US20230372476A1 (en) Novel use of mycobacterium tuberculosis extract

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20190315